4-(羟基甲基)-5-异丙基-1,3-二氧杂环戊烯-2-酮 | 188525-85-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 中文名称: 4-(羟基甲基)-5-异丙基-1,3-二氧杂环戊烯-2-酮
• 英文名称: 4-(hydroxymethyl)-5-(propan-2-yl)-2H-1,3-dioxol-2-one
• 英文别名: 4-(hydroxymethyl)-5-isopropyl-1,3-dioxol-2-one；4-(hydroxymethyl)-5-propan-2-yl-1,3-dioxol-2-one
• CAS: 188525-85-1
• 化学式: C₇H₁₀O₄
• mdl: MFCD18805748
• 分子量: 158.154
• InChiKey: ZECDJRPKAVJHKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(羟基甲基)-5-异丙基-1,3-二氧杂环戊烯-2-酮 在 四溴化碳 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以86%的产率得到4-(bromomethyl)-5-isopropyl-1,3-dioxol-2-one
  参考文献：
  名称：

  A general synthesis of dioxolenone prodrug moieties

  摘要：

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)02386-3
• 作为产物：
  描述：

  4-methyl-3-oxopentanoic acid benzyl ester 在 dirhodium tetraacetate 、 palladium hydroxide - carbon 对甲苯磺酰叠氮 、 草酰氯 、 氢气 、 三乙胺 、 N,N-二异丙基乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， -78.0~20.0 ℃ 、101.33 kPa 条件下， 生成 4-(羟基甲基)-5-异丙基-1,3-二氧杂环戊烯-2-酮
  参考文献：
  名称：

  A general synthesis of dioxolenone prodrug moieties

  摘要：

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)02386-3

文献信息

• COMPOUND HAVING TAFIA INHIBITORY ACTIVITY
  申请人：Amada Hideaki

  公开号：US20110213143A1

  公开（公告）日：2011-09-01

  Provided are compounds having superior TAFIa inhibitory activity. Specifically, there are provided compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: wherein A is a benzene ring or a pyridine ring; X is the formula —(CH 2 )—, the formula —(CH 2 ) 2 —, an oxygen atom, a nitrogen atom or a single bond; Y is the formula —(CH 2 ) 3 —NH—R 3 , the formula —(CH 2 ) 4 —NH—R 3 or a 2-aminopyridyl group; R 3 is a hydrogen atom, a C 1-6 alkyl group, or the formula —CO 2 R 4 ; R 4 is a C 1-6 alkyl group, the formula —CHR 5 OC(O)R 6 , or a substituent having the structure represented by the following formula Ia; R 5 is a C 1-6 alkyl group; R 6 is a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a phenyl group; R 7 is a C 1-6 alkyl group or a phenyl group; R 1 is a hydrogen atom, a halogen atom, a C 1-4 alkyl group substituted by 1-3 halogen atoms, a C 1-10 alkyl group, a C 1-8 alkoxy group, a C 3-8 cycloalkyl group, a C 3-8 cycloalkoxy group, a C 4-14 cycloalkylalkyl group, or a phenyl group; R 2 is CO 2 R 8 , or a tetrazolyl group; R 8 is a hydrogen atom, a C 1-10 alkyl group, or a substituent having the structure represented by the following formula Ib or Ic; m and n are each an integer of zero or one.

  提供了具有优异的TAFIa抑制活性的化合物。具体而言，提供了以下公式（I）或其药学上可接受的盐所代表的化合物：其中A是苯环或吡啶环；X是公式—（CH2）—，公式—（CH2）2—，氧原子，氮原子或单键；Y是公式—（CH2）3—NH—R3，公式—（CH2）4—NH—R3或2-氨基吡啶基；R3是氢原子，C1-6烷基或公式—CO2R4；R4是C1-6烷基，公式—CHR5OC（O）R6或具有以下公式Ia所代表的结构的取代基；R5是C1-6烷基；R6是C1-6烷基，C3-8环烷基或苯基；R7是C1-6烷基或苯基；R1是氢原子，卤素原子，被1-3个卤素原子取代的C1-4烷基，C1-10烷基，C1-8烷氧基，C3-8环烷基，C3-8环烷氧基，C4-14环烷基烷基或苯基；R2是CO2R8或四唑基；R8是氢原子，C1-10烷基或具有以下公式Ib或Ic所代表的结构的取代基；m和n各自为零或一的整数。
• WO2020163642A5
  申请人：——

  公开号：WO2020163642A5

  公开（公告）日：2023-02-09
• EP2361910
  申请人：——

  公开号：——

  公开（公告）日：——
• GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA
  申请人：Ardelyx, Inc.

  公开号：EP3921327A1

  公开（公告）日：2021-12-15
• [EN] GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA<br/>[FR] DÉRIVÉS D'ACIDE GLYCYRRHÉTINIQUE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'HYPERKALIÉMIE
  申请人：ARDELYX INC

  公开号：WO2020163642A1

  公开（公告）日：2020-08-13

  The present invention provides a compound of formula (I) or a salt thereof: (F ormula (I)) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) and as a result are useful in the treatment of hyperkalemia by preventing cortisol from being oxidised to cortisone and thus allowing it to occupy the mineralocorticoid receptor, thus stimulating potassium excretion.